Advances in Nutrition for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Management: Current Perspectives from the Bench to the Bedside
Open Access
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), has emerged as the most prevalent chronic liver disease worldwide, with an overall global prevalence of 30%Keywords
This publication has 8 references indexed in Scilit:
- Early Adoption and Prescribing Patterns of Resmetirom: A Multi‐Institutional National AnalysisLiver International, 2026
- Metabolic dysfunction-associated steatotic liver disease in adultsNature Reviews Disease Primers, 2025
- New approaches to the treatment of metabolic dysfunction-associated steatotic liver with natural productsiLIVER, 2024
- Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver FibrosisNew England Journal of Medicine, 2024
- EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive SummaryDiabetologia, 2024
- The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic reviewHepatology, 2023
- Coenzyme Q10 Supplementation for the Reduction of Oxidative Stress: Clinical Implications in the Treatment of Chronic DiseasesInternational Journal of Molecular Sciences, 2020
- Polyphenols and non-alcoholic fatty liver disease: impact and mechanismsProceedings of the Nutrition Society, 2015